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Abstract: Multiple sclerosis (MS) is one of the most common causes of neurological disability 
in young and middle-aged adults, with current prevalence rates estimated to be 30 per 100,000 
populations. Women are approximately twice as susceptible as males, but males are more likely 
to have progressive disease. The onset of the disease normally occurs between 20 and 40 years of 
age, with a peak incidence during the late twenties and early thirties, resulting in many years of 
disability for a large proportion of patients, many of whom require wheelchairs and some nursing 
home or hospital care. The aim of this study is to update a previous review which considered 
the cost-effectiveness of disease-modifying drugs (DMDs), such as interferons and glatiramer 
acetate, with more up to date therapies, such as mitaxantrone hydrochloride and natalizumab in 
the treatment of MS. The development and availability of new agents has been accompanied by 
an increased optimism that treatment regimens for MS would be more effective; that the number, 
severity and duration of relapses would diminish; that disease progression would be delayed; and 
that disability accumulation would be reduced. However, doubts have been expressed about the 
effectiveness of these treatments, which has only served to compound the problems associated 
with endeavors to estimate the relative cost-effectiveness of such interventions.
Keywords: multiple sclerosis, disease management, immunomodulatory drugs, cost-effectiveness, 
cost-effectiveness analysis, cost-utility analysis
Multiple sclerosis: the context
introduction
Multiple sclerosis (MS) is believed to affect more than 1 million people worldwide1 and 
is one of the most common causes of neurological disability in young and middle-aged 
adults.2–4 Prevalence rates vary considerably, though recent estimates put the global 
prevalence at any one time at 30 per 100,000 population,5 with rates highest in northern 
parts of Europe, southern Australia and the middle part of North America. Women are 
approximately twice as susceptible as males,2,6,7 but males are more likely to have pro-
gressive disease from onset.8,9 The onset of the disease normally occurs between 20 and 
40 years of age, with a peak incidence during the late twenties and early thirties.10,11 The 
relatively early age of onset results in many years of disability for a large proportion of 
patients, many of whom require wheelchairs and some nursing home or hospital care.12
While the cause and pathogenesis of MS are unknown, it is believed to be primarily 
an inflammatory condition in which autoimmune attack is associated with breakdown 
of the normal barrier separating blood from the brain. This leads to the destruction of 
myelin sheaths that normally facilitate nerve conduction. Although many episodes may 
be asymptomatic, the central nervous system has a limited capacity to repair areas of ClinicoEconomics and Outcomes Research 2009:1 62
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demyelination and repeated inflammatory attack often leads to 
scarring and loss of nerve cells themselves. It is the scarring and 
neuronal loss that probably underlie many of the chronic symp-
toms associated with MS, including limitation of mobility, 
ataxia, spasticity, pain, cognitive dysfunction and mood 
disturbance.13 MS is a diverse disease initially characterized, 
in most cases, by recurrent attacks of neurological dysfunc-
tion (relapses) followed by periods of complete or incomplete 
recovery (remissions). If recovery from relapses is incomplete, 
there will be stepwise increases in disability. This is relapsing-
remitting MS (RRMS) and accounts for between 65% and 
85% of cases at onset.13–15 However, within 10 years about 
50% develop the secondary progressive form of the disease, 
SPMS.16 Approximately 15% of patients experience progres-
sive MS from the outset with unrelenting advancement of the 
disease and maximum disability ensuing within months or over 
several years,16 while a small proportion have a benign course 
with minimal disability after 10 to 15 years.13 For those with 
RRMS, relapses occur unexpectedly, with symptoms appear-
ing over a few hours and maximum recovery, although not 
necessarily complete, usually taking several weeks. Typically, 
relapses may involve visual disturbance (eg, blurred or double 
vision), sensory problems (numbness, tingling and pain), limb 
weakness or paralysis, or any combination of the above. On 
rare occasions, more serious relapses can occur involving 
life-threatening emergencies such as brain stem inflammation 
leading to total paralysis and respiratory failure.
The costa of multiple sclerosis
A number of studies have attempted to assess the costs of 
MS.15,17–46 These have provided a wealth of information, but 
a variable picture emerges as to what constitutes the total 
cost of care. The full economic cost of MS is substantial, 
given that patients experience a major perturbation in their 
daily activities and the disease mainly affects young people, 
who are obliged to restrict their levels of economic activity, 
either temporarily or permanently.16 A review of the literature 
demonstrated that positive relationships exist between some 
components of the direct costs of the disease and indirect 
costs – the largest element of the cost of the disease.29 Studies 
have also shown that the total costs for patients increase with 
disability, as measured by the Expanded Disability Status Scale 
(EDSS).47 The EDSS scale is an instrument rating elements 
of neurological impairment, based upon an elaboration of the 
standard neurological examination. The scale ranges from 0 
(no impairment) to 10 (death from MS).
A 2005 Swedish study by Kobelt et al46 produced per 
patient total costs of €27,254 for mild MS (EDSS  2.0) and 
€52,457 for patients with severe MS (EDSS  6.5) (Figure 1). 
This study represents one of the largest undertaken in terms of 
the number of patients included (n = 2048). The major direct 
cost driver in the UK was ambulatory care, which the authors 
put down to high DMD usage in the UK, thus increasing 
outpatient visits to neurologists. Indirect costs at EDSS  2.0 
were calculated to be €10,142. However they double as 
disease severity increases to EDSS  6.5 (€20,545). This 
is mainly put down to the employment status of the patient 
(high levels of early retirement) which in turn increased the 
costs of informal care (EDSS  6.5 (€18,382).46 Indirect costs 
tend to be the largest component of the overall cost burden in 
MS,15,17,21,22,27,31,33–46 due to patients having to leave the labor 
market because of their disability and carers also having to 
leave employment situations to provide the necessary support 
and care.26 The question of whether the costs associated with 
informal care provided by friends and relatives should be 
included remains unclear, as they are difficult to quantify and 
value.17 It is accepted that specific inputs to the care process 
provided by informal carers should be included in direct costs, 
but the issue of whether production losses resulting from such 
care inputs should be included remains contentious.
The impact of MS on quality of life has also received 
considerable attention. The most common symptoms associ-
ated with MS include motor weakness, spasticity, sensory 
impairment, ataxia, tremor, nystagmus, dysarthria, vision 
changes, depression, cognitive abnormalities, fatigue, and 
bowel, bladder and sexual dysfunction. In addition, patients 
may also experience secondary complications such as urinary 
tract infections, respiratory infections, decubiti and muscle 
contractures.29 These primary and secondary symptoms 
result in people with MS suffering marked reductions in 
their quality of life (QOL), both during the early phases 
of the disease and as it increasingly impacts on levels of 
disability.17,48–52 Relapses have a particularly devastating 
effect on patients lives, since relapses are unpredictable in 
terms of timing, duration and severity, and therefore restrict 
patients ability to plan their lives, especially for major events 
such as holidays and family celebrations.52
While MS has an impact on all members of the family, the 
major responsibilities for care tends to rest with the primary 
carer – in most cases the spouse – who has to adopt other functions 
and responsibilities, including wage earner, homemaker, primary 
aCurrencies have been reported in Euros and the specific currency used in 
the study. Conversion of currencies was calculated for the 1 January of 
the currency rate year stated by the author. Every effort has been made to 
maintain the accuracy and integrity of the original estimate.ClinicoEconomics and Outcomes Research 2009:1 63
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parent as well as carer.53 The physical, mental and financial 
burdens placed on carers are often significant and can lead to 
stress, fatigue and depression and, in many cases, the quality of 
life of the carer reflects that of the patient.54
The next section outlines the aim and objectives of this 
review and describes the approaches adopted in the collection 
and assessment of relevant studies.
Purpose of study and methods 
employed
The aim of this study is to examine the approaches used to 
assess the cost-effectiveness of disease modifying therapies in 
the treatment of MS such as interferons and glatiramer acetate, 
and to include recent additions to the formulary such as mitax-
antrone hydrochloride (MH) and natalizumab in the treatment of 
MS. Electronic databases including Medline and Pubmed were 
searched for studies on the cost-effectiveness of interventions 
in the field of MS. Additional studies identified through search-
ing bibliographies of related publications and using the Google 
internet search function. Included studies were assessed using 
standard critical appraisal criteria. Search terms were: Multiple 
Sclerosis, Disease management, Immunomodulatory drugs, Cost-
Effectiveness, Cost-Effectiveness Analysis, Quality of life, Eco-
nomic Evaluation, Cost Analysis, Cost benefit, Cost-utility, 
cost-utility analysis, Cost minimization, Pharmacoeconomics.
inclusion criteria
•  Language of publication restricted to English.
•  Studies that focused on the diagnosis, prevention and or 
treatment of MS and reported a synthesis of associated 
costs and benefits.
•  Studies that compared treatment with immunomodulatory 
drugs; and used patient based outcomes such as relapses, 
disease progression, and side effects.
•  Studies restricted by date of conversion rates pre 1999.
•  Studies published in a peer reviewed journal.
Exclusion criteria
•  Non-English language publications
•  Abstracts presented at conferences
•  Studies not available in full text.
Studies were excluded if they did not conform, in the 
main, to the recognized conventions for health economic 
appraisals,55 but some of these provided useful contextual 
information for this review.
The next section examines the range of available therapies 
available for the treatment of MS and provides an overview 
of the discussions relating to the relative effectiveness of 
such interventions.
The clinical effectiveness 
of treatments in MS
It has been argued that the management of patients with 
MS should begin at the time of diagnosis.56 There are three 
aspects to the management of MS:13
•  the prevention of disease progression and relapse rates;
•  the treatment of acute exacerbations;
•  the treatment of chronic symptoms.
Prior to the advent of disease-modifying drugs (DMDs), 
the mainstay of MS therapy was symptomatic treatment 
(both physical and pharmacological) and this still remains 
a central tenet of patient management in conjunction with 
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Figure 1 Costs (Euros) of multiple sclerosis by disease severity, UK 2005.
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disease-modifying therapy. Steroids are the treatment for acute 
exacerbations, but these do not affect consequent disability, 
while chronic symptoms are treated by physiotherapy and 
anti-spasticity drugs, and fatigue by psychological and physi-
ological treatments and by neurorehabilitation.13 Counseling 
is also important and may be given by health professionals 
or more informally through patient support groups and MS 
charities. However, the quality and scope of therapies and 
services available to sufferers of MS differ widely within 
countries and across countries.32,57
In relation to RRMS, the goals of treatment ideally 
are to:12,58,59
•  treat acute relapses;
•  improve health-related quality of life;
•  reduce the frequency and severity of relapses;
•  delay disability accumulation; and
•  postpone the onset of the progressive phase of the disease.
The development and availability of DMDs was accom-
panied by an increased optimism that the above goals could 
be achieved, and these technologies have been approved by 
a number of regulatory authorities for use in the treatment 
of MS.
Evidence from randomized controlled trials60–72 suggest 
that interferons, as a class, reduce both relapse rate and 
severity, and also delay the progression of disability espe-
cially in relapse remitting MS. There is also a marked and 
rapid reduction in MS disease activity, as measured by 
repeated brain magnetic resonance imaging (MRI) scans.12,73 
However, doubts have continued to be expressed about the 
validity of such evidence and the extent to which interferons 
are effective3,13 and the extent of their benefits relative to 
side effects and costs.74 In addition to the clinical trials of 
interferons in MS, a number of reviews have aimed to assess 
the effectiveness of these therapeutic interventions,3,13,58,75–83 
but arriving at a consensus has been problematic due to the 
methodological quality of trials undertaken.3,79,84,85 It has been 
argued that “well conducted trials using outcome measures 
with clinical significance for groups of patients with differ-
ent types of multiple sclerosis and long term follow up are 
needed if the evidence base of treatment for the disease is 
to be improved.”85
Glatiramer acetate consists of a random mixture of 
four naturally occurring amino acids, which was initially 
developed to mimic myelin basic protein, one of the 
antigens thought to be involved in the pathogenesis of 
MS.86 It has a different mechanism of action to that of the 
interferons and appears to have a more favorable tolerability 
profile,59,87 but has an efficacy profile broadly similar to that 
of the interferons.87 In a review of its effectiveness, it was 
concluded that the extent of benefits were not clear,13 while 
studies which have reported on the follow-up long term 
effects of glatiramer acetate,87,88 have also been confronted 
with methodological issues, which have tended to cloud the 
quality of these studies.87 The 2008 REGARD study89 which 
compared the use of interferon beta-1a (IFNβ-1a) (Rebif®) 
and glatiramer acetate in patients with RRMS, found that 
with the outcome measure tested – time to first relapse – there 
was no significant difference between the two treatment 
groups. However, the authors acknowledged that “the abil-
ity to predict clinical superiority in a head to head study on 
the basis of results from separate placebo-controlled studies 
of each drug might be restricted and is challenged by a trial 
population with low disease activity”.
MH acts to “damage” rapidly dividing cells, such as 
those in the immune system and is usually used, in combi-
nation with other drugs, as a type of chemotherapy to treat 
certain types of cancer. In recent years it has also been used 
to treat very active RMSS or SPMS. During the period of 
treatment, mitoxantrone appears to work in MS by suppress-
ing the immune system and giving the nervous system a 
chance to recover from recent relapses.90 MH was licensed 
for the treatment of MS in October 2000 by the Food and 
Drug Administration (FDA), but it is not licensed in some 
other countries for the treatment of MS and is used as an 
“off-licence” treatment for MS.90 According to the MIMS 
study,91 the high dose of MH (12 mg/m2 every 3 months 
for up to 24 months) was “effective and generally well 
tolerated, and significant treatment effects were found by 
all of the outcome measures”.91 Although beneficial effects 
were also observed with the low-dose drug when compared 
to placebo, they were not as convincing as with the higher 
dose. The authors believed that “mitoxantrone provides a 
new therapeutic option for people with worsening relapsing 
remitting MS, or secondary progressive MS”.91
Natalizumab is a monotherapy DMD approved for use 
by the FDA and the European Union (EU) in June 2006. It is 
one of the more recent additions for treatment in MS. It is 
thought that natalizumab exerts its therapeutic efficacy by 
blocking the pass of T cells, a specific immune cell which 
plays a major role in the pathogenesis of MS, through the 
blood–brain barrier, thus preventing these cells reach the 
central nervous system.90 Natalizumab is currently licensed as 
a single disease modifying therapy for 2 subgroups of highly 
active relapsing-remitting multiple sclerosis (HARRMS) 
sufferers and are classed as: “patients who have had 2 or 
more relapses with one or more gadolinium enhancing ClinicoEconomics and Outcomes Research 2009:1 65
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lesions on brain MRI or a significant increase in T2 lesion 
load compared with a recent MRI and patients who have 
failed to respond to a full and adequate course of inteferon b. 
Patients should have had at least one relapse in the previous 
year while on therapy, and have at least nine T2-hyperintense 
lesions in cranial MRI or at least one gadolinium-enhancing 
lesion.”92 Results from the clinical effectiveness AFFIRM 
trial93 are very favorable, with Natilizumab reducing the 
risk of sustained progression of disability by 42%, with the 
cumulative probability of progression being 17% compared 
to 29% in the placebo group. The rate of relapses was reduced 
by 68% and led to an 82% reduction in the accumulation of 
new or enlarged hyperintense lesions.94 Natalizumab costs 
£1,130 (€1,167) per 300 mg vial, with an annual cost of 
approximately £14,730 (€15,214) per patient95 (excluding 
hospital outpatient costs).
The result of this uncertainty surrounding the effective-
ness of these disease therapies in the treatment of MS has 
compounded the problems associated with endeavors to esti-
mate the relative cost-effectiveness of such interventions.
The cost-effectiveness  
of DMDs in MS
In addition to the uncertainties associated with the clinical 
effectiveness, there are a number of issues that have resulted 
in a wide range of estimates of cost-effectiveness and ham-
pered attempts to establish any consensus relating to the 
cost-effectiveness of DMDs. These issues relate to the appro-
priateness of the data used from the trials, the natural history 
or epidemiological data used to extrapolate to longer time 
horizons and the structure of models used. Methodological 
issues relating to the nature, derivation and quality of data 
used to populate the models and specific inclusion and exclu-
sion criteria in terms of parameter selection can often render 
any estimations of cost-effectiveness less than robust.
While, increasing use has been made of Markov models, 
which allow for the management of patients in and between 
different health states over time, to assess the relative cost 
effectiveness of DMDs in MS, problems are still too read-
ily apparent. The timescales involved frequently extend 
beyond the duration of clinical trials developed to assess 
clinical effects, and there is a lack of consensus as to the 
longer-term effects of DMDs. The wide range of estimates 
reflects the difficulties inherent in translating the results from 
clinical trials into models that assess the cost-effectiveness 
of interventions in MS, while the lack of homogeneity in 
study design also contributes to the wide variation in the 
estimates of cost-effectiveness and the difficulty of arriving 
at a consensus. Short-term analyses avoid the problems of 
attempting to extrapolate from clinical data, but fail to do 
justice to the duration of the illness and its progression over 
time, while longer-term studies may capture the longer-term 
effects, but do so with only limited evidence to substantiate 
the extrapolations from relatively short-term data and the 
assumptions underlying the construction of the models (for 
a full list of studies see Table 1). For example, efficacy data 
from the EVIDENCE trial66–68 which lasted for 64 weeks was 
utilized in a model that simulated effects for a 4-year period. 
Guo96 explained that the relatively short modeling timeframe 
was used to give consistency to “many US Payers realistic 
time horizon”, and also to maintain analytical relevance 
with the likelihood of newer IFNβ-1a treatments becoming 
available during the projected time span. Further, clinical 
trial data from the IFNβ-1b Study60,64,65 is utilized 9 times 
in various studies and, while, the trial lasted for 3 years, 
models have been developed15,97–103 that cover timeframes 
of 10 years up to 40 years.
However, recent studies have generally produced 
more favorable cost-effectiveness ratios, benefiting from 
more relevant and up-to-date data relating to disease 
progression15,83,92,96,98,99,102,111,113,118 and it may be reasonable 
to conclude that the cost-effectiveness of interventions 
improves when longer time perspectives are employed, and 
the models more accurately reflect the progression of disease 
experienced by patients.15,96 As well as the time horizon, 
the estimates are highly sensitive to the approach taken to 
discounting costs and benefits; the cost of the therapies; the 
costs of patient management; disease progression, with and 
without treatment, and what happens to patients when they 
stop treatment; the impact of MS on carers in terms of utility 
loss and costs incurred; the effect of non-responders and 
adverse events associated with the therapies; the relationship 
between disability levels and utility losses and the extent to 
which indirect costs are included.
In addition, the assignment of utility scores to various 
“states” in MS have proved to be very contentious. These 
states are often founded on EDSS,47 but concerns relating to 
its large inter-rater reliability, its ordinal nature and its unnec-
essary focus on certain categories of functional impairment 
have led to questions being posed regarding the validity of 
results derived from its use.7,104 The utility values attached 
to each of the EDSS states have varied considerably. It has 
been estimated that the difference between EDSS state 0 and 
3.0 represents a 30% reduction in a patient’s quality of life, a 
similar reduction in quality of life from state 3.0 to state 7.0, 
while states 9.0 (helpless bed patient; can communicate and eat) ClinicoEconomics and Outcomes Research 2009:1 66
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and 9.5 (totally helpless bed patient; unable to communicate 
effectively or eat/swallow) have been valued at less than 
zero).98 Variations in the utility scores associated with disease 
categories, the impact of relapses and the utility losses resulting, 
plus the speed of disease progression have all contributed to 
the difficulties involved in estimating the quality-adjusted life 
year (QALY) losses for a patient suffering with MS.
Cost-effectiveness and cost-utility 
analysis by drug
This paper focuses on recent additions to the literature and 
develops the base established in a previous review,105 but 
in order to provide a suitable context, a brief discussion of 
“older” studies and their limitations is presented below.
The perspective employed in the studies had a major 
effect on the cost-effectiveness ratios. For example, 
Brown et al97 examined the cost-effectiveness (CE) of 
IFNβ-1b in slowing disability progression in patients with 
RRMS. The model was designed to estimate costs and 
outcomes for cohorts of 1000 females and 1000 males 
followed 40 years from onset, with the primary health 
outcome being cost per disability year avoided (DYA). 
Results showed that over the natural history of RRMS, 
females were expected to achieve 10.5% fewer disability 
years (9% after discounting at 5%). The cost per DYA was 
relatively high with CAN$189,230 (US$124,892), and 
increasing to CAN$274,842 (US$181,395) after discounting 
at 5%, with the authors recognizing that the cost perspective 
they adopted was “relatively narrow” as they only included 
direct costs and no indirect costs. The 2002 study by Nuijten15 
used clinical data64 to evaluate the cost-effectiveness of both 
IFNβ-1a and IFNβ-1b in the treatment of MS versus standard 
care. A Markov model was designed containing 4 mutually 
exclusive Markov states corresponding to 4 EDSS severity 
points and the incremental cost-effectiveness was measured 
by cost per QALY. Total per patient costs (discounted at 6%) 
for IFNβ arm was £221,436 (US$364,993) versus £51,214 
(US$84,416) for the no treatment (standard care) group. The 
higher costs for the IFNβ arm derived from the cost of IFN 
((£179,367) (US$295,651)). The average QALY gained was 
estimated at 28.2 versus 24.9 for the standard care group, 
a gain of 3.3 QALYs. The authors conclude that using IFN 
as preventative treatment “may not be fully justified from 
a health-economic perspective”, but they acknowledge that 
it is “associated with an improved effectiveness compared 
with no preventative treatment.”
Parkin et al100 evaluated the cost-effectiveness of IFNβ-1b 
in patients with RRMS. The clinical data was taken from ClinicoEconomics and Outcomes Research 2009:1 70
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2 trials by the IFBN Multiple Sclerosis Study Group60,64 
with patient, cost and quality of life data collected from 
questionnaires administered (EQ-5D and MSQOL). When 
discounted at 6%, IFNβ-1b was shown to reduce relapse by 
1.52 per patient (over 5 years) giving a cost-effectiveness 
ratio of £28,700 (US$44,428) per relapse avoided. With a 
QALY gain of 0.054, this gave a cost-utility ratio of £809,900 
(US$1,253,725) per QALY gained. Allowing for effects 
of progression over 5 years, the QALY gained reduces to 
£328,300 (US$508,208). Parkin’s study100 cited the lack of 
severe EDSS scores and no indirect costs as limitations of 
the study. However, new EDSS states were added in for the 
1999 update107 to give a “range of different EDSS levels”. 
In this update,107 new data were also collected for costs and 
QOL with the patients split into two groups: patients who had 
suffered a relapse in the last 6 months and those who had not. 
A decision analytic model was then constructed using EDSS 
health states to calculate both the cost-effectiveness and 
cost-utility. The authors concluded that IFNβ-1b produces 
short-term QOL gains in patients with RRMS, however, the 
QALY gains are small and thus “the benefits are achieved 
only with a large additional cost”.
Studies that employed a societal perspective have, on 
occasions, produced more favorable cost-effectiveness 
ratios. For example, Forbes et al’s 1999 study74 evaluated 
the cost-utility of IFNβ-1b in SPMS in 132 ambulatory 
patients studied from a healthcare sector perspective but 
employed a societal perspective in the sensitivity analysis. 
The cost per QALY gained, from a healthcare perspective 
was estimated to be £1,024,393 (US$1,602,509) with a 95% 
confidence interval of £276,191 (US$432,059) to £1,484,824 
(US$2,322,784). From a societal perspective, the authors 
claim the cost per QALY gained reduced by “only 0.2%” to 
around £1,022,344 (US$1,679,507). The authors concluded 
that it was “probably appropriate to allocate more resources 
to people with secondary multiple sclerosis, but access to 
IFNβ-1b should be restricted.”Kendrick et al’s 2000 study106 
examined the CE of long term IFNβ-1a, and set out to 
challenge the assumptions of the clinical and cost benefit of 
IFNβ-1a used in previous CE studies. The model estimated 
the rate of disability progression in the RRMS patients 
receiving either IFNβ-1a or standard care (ie, without DMDs) 
and was extrapolated to produce annual EDSS scores for a 
period of 20 years. Results of the model showed high disease 
progression within the placebo arm (progression to EDSS 
stage II by 4 years from start of study) compared to patients 
receiving IFNβ-1a (progression to stage II by 11 years) 
Further extrapolation showed the same sets of patients 
progressing to stage III by 9 and 20 years respectively. 
Total costs per QALY (discounted at 6%) ranged from 
£27,000 (US$42,237) to £38,000 (US$59,445) depending 
on the length of IFNβ-1a treatment. Once societal costs 
(all costs including both direct and indirect) were included 
in the model, it was claimed that treatment of RRMS with 
IFNβ-1a could provide “substantial” cost savings to society, 
increasing with treatment duration. Phillips et al102 cited the 
similar assumptions and lack of ability to “closely reflect 
clinical practice” in the study. However, this study, which 
followed Parkin’s100 data and model closely, also considered 
the impact on indirect costs in the analysis to obtain a 
wider societal perspective and arrived at a more favorable 
cost-effectiveness ratio.
The next section summarizes and discusses more recent 
studies grouped by the disease modifying therapy.
interferon
A US study by Guo et al96 examined the clinical and economic 
effectiveness of the treatment of RRMS using high-dose/high 
frequency subcutaneous (SC) IFNβ-1a, compared with low-
dose weekly intramuscular (IM) IFNβ-1a. The study was 
performed from the US Payer’s perspective with a discrete 
event simulation model (DES) populated with data mainly 
taken from the EVIDENCE trial.66–68 The use of the DES 
model, over the more commonly used Markov model, was 
designed to utilise its flexibility when comparing various 
treatment scenarios, with the authors arguing that a Markov 
model “forces a disease into a few mutually exclusive states 
within a fixed time”, eg, fixed EDSS stages. The model 
simulated 1000 pairs of patients over a 4 year timeframe. 
Discounting was calculated annually at 3% beyond the 
first year. The total mean costs per patient (discounted) were 
US$79,890 (€67,477) with SC IFNβ-1a, compared with 
US$74,485 (€62,912) with IM IFNβ-1a. However, even 
though this means an increase of US$5405 (€4,565) per 
patient, SC IFNβ-1a was estimated to save 23 relapse-free 
days per patient – an incremental cost-effectiveness ratio 
(ICER) of US$10,755 (€9,084) per relapse prevented and 
US$ 232 (€196) per relapse-free day prevented. The authors 
estimated that there was a 95% probability that the cost per 
relapse prevented would be below US$20,000 and the cost per 
relapse-free day would be below US$420. They concluded 
that based on 1000 replications of the 1000 pairs of patients 
from the EVIDENCE trial, SC IFNβ-1a would have greater 
health benefits over 4 years than IM IFNβ-1a. However, this 
study had a limited time duration and did not include indirect 
costs in the analysis. Further, the cost-effectiveness was ClinicoEconomics and Outcomes Research 2009:1 71
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measured in relation to relapses prevented and relapse-free 
days and therefore make it difficult to gauge the relative 
cost-effectiveness compared with other products.
Iskedjian et al’s 2005 Canadian study108 estimated the 
cost-effectiveness of Avonex® (IFNβ-1a) compared with 
current treatment of clinically definite multiple sclerosis 
(CDMS) following a single demyelinating event (SDE). 
The study performed both a cost-effectiveness (CEA) and 
cost-utility analysis (CUA) from the societal and healthcare 
sector perspectives. A Markov model was designed to gener-
ate the time spent in the pre-CDMS state (monosymptomatic 
life years (MLY)) and quality adjusted monosymptomatic life 
years gained (QAMLY) for the CEA and CUA perspectives 
respectively. Clinical data on the progression to CDMS was 
derived from the CHAMPS study69 and a 1989 Canadian 
study.8 Costs were derived from two Canadian cost of illness 
(COI) studies.26,109 The time horizon was set at 12 years by 
doubling the projected median time (6 years) a patient on 
Avonex would progress to the CDMS state. This enabled 
the authors to analyze the outcomes of the majority of the 
patients who suffered an SDE. The time horizon for the CUA 
model was 15 years. This was the median time for progres-
sion to CDMS state (6 years) added to the median time of 
progression to EDDS 3 (approx 7 years). Outcomes at 20 and 
30 years were captured through sensitivity analysis. From the 
Ministry of Health (MoH) perspective, the incremental cost-
effectiveness of Avonex per MLY gained was CAN$53,110 
(€37,658). In the CUA, the cost per QAMLY gained was 
CAN$227,586 (€161,371). From the societal perspective, 
the CEA ratio was CAN$44,789 (€31,758) per MLY gained 
and CAN$189,286 (€134,214) per QAMLY gained. The 
results of this study are favorable towards both the clinical 
and cost-effectiveness of Avonex for patients experiencing 
an SDE. Additionally the authors suggest that the overall 
incremental cost-effectiveness of Avonex increases if treat-
ment is administered pre-CDMS.
Kobelt et al’s 2003 study99 employed a Markov model 
to estimate the cost-effectiveness of IFNβ-1b treatment in 
patients with RRMS or SPMS. The study aimed to address 
how “treatment affects disease progression from diagnosis 
to severe disability”. Using clinical data from two 5-year 
trials,64,70 natural history data8 and cost-utility data,17 Kobelt’s 
study was performed from both the healthcare sector and 
societal perspective in Sweden. The model used the EDSS 
scale to define disease parameters and captures a mix of 
patients with both RRMS and SPMS according to the level 
of exacerbations suffered. The model consisted of 40 cycles 
(10 years) that is four 3-month cycles per year, with the 
IFNβ-1b intervention lasting 12 cycles (3 years) discounted 
at 3%. Mean total costs in the placebo arm amounted to 
€399,200 with the intervention €400,700. Cost per QALY 
gained was €7,800 (after 12 cycles). However, QALY 
gained increased to €38,700 with IFNβ-1b when treatment 
was increased to 54 months, and with potential cost savings 
being evident in the more severe states for the same time 
scale. At a willingness to pay (WTP) threshold of €50,000, 
the probability that IFNβ-1b was cost-effective was around 
80%, which would increase to 90% at a WTP threshold of 
€80,000. The sample contains an SPMS subgroup combined 
with an RRMS subgroup from a differing trial as the authors 
had selected these due to their disease progression, rather 
than on relapse rate. Therefore the analysis supported the 
authors’ hypothesis that there is a larger treatment effect 
the more active the disease. Kobelt’s study claimed that the 
combination of RRMS and SPMS patients from two separate 
studies8,64,65 might result in a population of two groups that 
“were not fully comparable”. The issue of non-compliance in 
the clinical trials was also highlighted as a factor that might 
artificially improve the cost-effectiveness – a problem also 
seen in other studies.92,103
Kobelt et al’s 2000 study110 estimated the cost-
effectiveness of treatment of SPMS with IFNβ-1b. Using 
data from a population-based observational study,17 a Markov 
model was developed to estimate the incremental cost 
per QALY for treatment with IFNβ-1b compared with no 
treatment. Taking a Swedish societal perspective, the model 
was based on a 10 year time horizon (in cycles of 3 months) 
with Markov states based on EDSS measurements. The 
mean total cost of a relapse was estimated to be SEK 25,700 
(€2,714). For the base case, the incremental QALY gain over 
10 years was SEK 55,500 (€5,862) resulting in a cost per 
QALY of SEK 342,700 (€36,194) (including all costs). When 
indirect costs were excluded, the cost per QALY increased 
to SEK 542,000 (€57,243). Employing a cost-effectiveness 
threshold of US$60,000 (€51,418), the vast majority of cost-
utility ratios were either below or equal the threshold.
Kobelt’s 2002 study111 used an adapted version of the 
Markov model described above, populated with natural his-
tory data of MS based on the London, Ontario study.8 The 
inclusion of these data was to reflect more accurately disease 
progression rather than using progression rates from clinical 
trial data which could result in potential bias. The model had 
6 disease progression steps as opposed to the seven the earlier 
model. Using the same Swedish cost data,17 and discounting 
at 3%, this cost-utility analysis produced cost of care savings 
of SEK 177,400 (€18,736), of which SEK 11,600 (€1,225) ClinicoEconomics and Outcomes Research 2009:1 72
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were due to relapse reduction. When all costs (including 
indirect costs) were included, the potential savings were 
SEK 150,300 (€15,874). The QALY was also estimated at 
SEK 257,200 (27,164) in the base case. The authors attrib-
uted the higher cost-utility ratio of SEK 542,000 (€57,243) 
compared with the previous study to “the underestimate 
of the progression of disability”. The study concluded that 
the cost per QALY falls below the threshold of US$30,000 
(€25,709) “that in previous studies has been accepted as 
cost-effective in Sweden”.
Lazzaro et al’s 2009 study112 is the most recent economic 
evaluation of IFNβ-1b in the treatment of MS, the cost of 
treatment of IFNβ-1b from the diagnosis of clinically isolated 
syndrome (CIS) was compared to the cost of treatment once 
conversion to clinically definite MS (CDMS) has happened, 
from the Italian healthcare sector and societal perspectives. The 
study incorporated the patients enrolled in the BENEFIT study71 
into a 25-year epidemiological model. From the healthcare 
sector perspective, the annual IFNβ-1b treatment costs per 
patient amounted to €7,150, €19,105 and €32,767 for the CIS, 
RRMS and SPMS patients respectively. IFNβ-1b was the major 
cost driver for CIS patients, with hospital admissions being 
the largest cost component for RRMS and SPMS patients. 
Conversely, from the societal perspective, the annual cost of 
treatment rose to €7,307, €25,349 and €45,841 for the CIS, 
RRMS and SPMS patients respectively. The cost drivers for 
the CIS patients were again the cost of IFNβ-1b. However, 
the major cost drivers for both the RRMS and SPMS patients 
were loss of working days combined with patient and family 
resources. The QALYs gained achieved statistical significance 
(P  0.0001) with 7.84 QALYs gained for the CIS arm, com-
pared to 7.49 for the untreated arm. The authors concluded that 
early treatment of IFNβ-1b was cost-effective from the health-
care sector point of view with an incremental cost-effectiveness 
ratio (ICER) of €2,575 falling well below the unofficial 
acceptable incremental QALY range of between €12,000 and 
€60,000. The study also suggested that early treatment of CIS 
with IFNβ-1b would significantly reduce disease progression 
to CDMS thus making it cost-effective in the long term.
A 2003 study by Lepen et al113 used econometric modeling 
of the 4 year data from the PRISMS study72 and, using the 
area under the EDSS-time curve (AUC-EDSS) as an inte-
grated measure of disability, calculated the effectiveness of 
IFNβ-1a as number of EDSS-months of disability saved. 
By projecting the data over 10 and 20 years, the authors 
hypothesized that because the model would produce “real 
cost-effectiveness results in terms of cost per EDSS month 
of disability prevented”, it may be more “valid and more 
clinically meaningful than cost-utility ratios”. Cost data was 
derived from Murphy et al’s 1998 cost of illness study.21 
The model reported that after 10 years, the IFNβ-1a arm 
experienced 484 EDSS-months of disability compared to 
605 for the placebo arm. For 20 years, these figures increased 
to 1266 and 1587 respectively. For the UK, the total cost of 
care (including standard care and IFNβ-1a treatment was) 
£243,141 (€389,711) for 10 years. This gave a cost per 
EDSS-month saved of £453 (€726). At 20 years, the total costs 
rose to £448,602 (€719,029) with the cost per EDSS-month 
saved reducing to £222 (€356). The authors concluded that 
maintaining the patient at their current EDSS level reflected 
the increasing economic benefit of IFNβ-1a. Secondary 
analysis in the study confirmed that using a one dose of 44 µg 
rather than three doses of 22 µg per week saved 15 EDSS-
months over 10 years, giving a cost of £14,000 (€22,440) 
per EDSS-month saved. However, the authors acknowledged 
the limitation of using the AUC measure as “a patient with a 
period of improvement followed by deterioration might have 
the same AUC as one who showed deterioration followed by 
improvement”. This, the authors add, may lead to “erroneous 
disability projections” if modeled over 20 years.
Glatiramer acetate
In 2001, Bose et al114 estimated the cost-effectiveness of 
glatiramer acetate in the treatment of RRMS using clinical 
data from the pivotal clinical trial for Copaxone®88,115 com-
bined with published cost and natural history data. The EDSS 
states used ranged from 0 to 7. The perspective was from the 
healthcare sector so no indirect costs were included. The cost 
per relapse, calculated from Parkin,100 was £2,362 (€3,786). 
Base case estimates for both 6 and 8 years demonstrated that 
cost-effectiveness improved as the time horizon lengthens 
with £13,626 (€21,840) and £11,000 (€17,631) cost per 
relapse avoided respectively. Cost per disability unit avoided 
was estimated at £11,935 (€19,130) and £8,862 (€14,204) for 
6 and 8 years respectively. When the duration of a relapse 
was one month instead of two, the cost per QALY over 
8 years was £64,636 (€103,600). Further, after discounting 
at 6%, the cost per relapse avoided was £12,092 (€19,381), 
with cost per QALY being £24,870 (€39,862). Differential 
discounting (6% on costs and 1.5% on benefits) resulted in 
the cost per relapse at 8 years being £10,184 (€16,323) and 
cost per QALY £20,929 (€33,545). Finally, when indirect and 
informal costs were added (by doubling the cost per relapse 
to £4,724 (€7,572)) the cost per relapse avoided declined 
from £11,000 (€17,631) to £8,632 (€13,836), and cost per 
QALY declined to £17,733 (€28,423) in the base case. ClinicoEconomics and Outcomes Research 2009:1 73
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However, in terms of the cost-effectiveness of glatiramar 
acetate, Bose used natural history data to fill in a gap where 
clinical data was not available for the placebo arm patients 
beyond 35 months. Finally, in terms of the cost per QALY 
ratio being driven by utility loss associated with relapse, the 
authors conclude that analysis “would have been improved 
with more robust data”.
Natalizumab
The study by Gani et al92 examined the cost-effectiveness 
of natalizumab (Tysabri) compared with IFNβ, glatiramer 
acetate and best supportive care in patients with highly 
active RRMS (HARRMS). Using previously published data, 
including efficacy data from the AFFIRM study,93 a 30-year 
model was developed from a societal perspective, based on 
a previous study by Chilcott.98 Of the 3 disease modifying 
treatments, natalizumab resulted in the most cost-effective 
ICER of £2,300 (€3,348) per QALY gained, compared with 
IFNβ’s ICER of £2,000 (€2,911) and glatiramer acetate’s 
ICER of £8,200 (€11,937) per QALY gained. Sensitivity 
analysis showed that the cost-effectiveness of natalizumab 
reduced when the timeline horizon was reduced to 20 years. 
When viewed from the healthcare sector perspective, the 
cost-effectiveness also fell. With a WTP threshold set at 
£30,000 (€43,671) per QALY, the probability of natalizumab 
being cost-effective was 89%, 90% and 94% respectively 
compared to IFNβ-1b, glatiramer acetate and best sup-
portive care (BSC) respectively. In conclusion, the authors 
suggested that natalizumab for patients with HARRMS was 
more cost-effective than IFNβ, glatiramer acetate and best 
supportive care if the societal WTP was higher than £8,200 
(€11,937) per QALY or £26,000 (€37,849) per QALY from 
the healthcare sector perspective. However, the authors 
acknowledged the limitations linked to the combining of 
RRMS and SPMS patients from the AFFIRM study93 and 
the London Ontario dataset,8 while they did not include all 
indirect costs and also experienced the same uncertainty as 
Kobelt94 when considering non compliance.
Kobelt et al’s 2008 study94 modeled the cost-effectiveness 
of natalizumab compared with current practice. Employing a 
Swedish healthcare sector and societal perspective, Kobelt’s 
study used existing literature – AFFIRM,93 Ontario data set8 
and cost data from 2 previous Swedish studies116,117 – and 
developed a model that covered a 20-year time frame with 
effects and costs discounted at 3%. The total cost of natil-
izamub was €609,850, €3,830 less than standard care, with 
a cost per QALY dominating, thus representing a best case 
scenario. The cost of natalizumab was €352,175 with a cost 
per QALY of €38,000, from the healthcare sector perspective. 
From the societal perspective, natalizumab was dominat in 
55% of cases and the probability that the cost per QALY 
was  €50,000 was 75%. The authors concluded that for 
the population data used and from a societal perspective, 
“natalizumab provides an additional health benefit at a similar 
cost to current DMDs”.
Both these studies suffered from uncertainties, while 
Kobelt et al also expressed concern that all the RRMS patients 
started at EDSS 3.5. Additionally, the open-label extension 
of the AFFIRM study was stopped due to the appearance of 
progressive multifocal leukoencephalopathy in 2 patients, all 
of which resulted in Kobelt et al concluding that the “analysis 
has to be treated with caution”.
Thus even with newer therapies the uncertainties relating 
to their respective uncertainties remain.
Comparison studies of disease  
modifying therapies
interferon and glatiramer acetate
Bell et al’s 2007 study118 compared the cost-effectiveness 
of 4 immunomodulatory drugs: SC glatiramer acetate 
and 3 IFNβs: IM IFNβ-1a, SC IFNβ-1a and SC IFNβ-1b. 
A Markov model populated by data from the literature was 
developed to assess the cost-effectiveness of 5 treatment strate-
gies for RRMS patients compared to symptom management 
alone. The model incorporated the EDSS scale with 7 specific 
transition health states with the time horizon set at 13 years 
(approximation of a patient’s lifetime with MS) and was 
measured from the US societal perspective. Total costs for the 
lifetime of a patient were calculated at US$295,586 (€217,919) 
for symptom management arm and US$352,760 (€260,071), 
US$364,267 (€268,554), US$377,996 (€278,676) and 
US$358,509 (€264,309) for each drug arm respectively. When 
direct medical costs were compared, the additional costs of drug 
treatment were partially offset by cost savings in MS related 
medical costs. The SC glatiramer acetate arm had the largest cost 
offset with 24% saved compared to 17% to 22% cost saved by 
beta IFNs. Overall, the SC glatiramer acetate patients received 
greater cost benefits with the incremental cost per QALY of 
US$258,465 (€190,552) compared to US$337,968 (€249,165), 
US$416,301 (€306,916) and US$310,691 (€229,056) for the 
3 IFNβ treatments respectively. The authors concluded that all 
4 drug treatments were associated with increased benefits for 
RRMS patients compared to symptom treatment alone, with 
SC glatiramer acetate being best strategy.
Prosser et al103 compared the cost-effectiveness of 3 immu-
nomodulatory drugs (IFNβ-1a, IFNβ-1b and glatiramer acetate) ClinicoEconomics and Outcomes Research 2009:1 74
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for newly diagnosed non-PPMS, compared with no treatment. 
A state transition model was developed with a 10-year 
treatment duration from the societal perspective. Costs 
were discounted at 3% per year. From base case analysis, 
IFNβ-1a provided more health benefits and resulted in an 
ICER of US$1,838,000 (€1,575,088)/QALY for men and 
US$2,218,000 (€1,900,732)/QALY for women. With 10-year 
treatment of IFNβ-1a, this resulted in gains of 11 QALYs for 
men and 13 for women. IFNβ-1b proved to be less effective 
and more costly than the no treatment. Glatiramer acetate 
had a higher ICER, but lower cost compared to IFNβ-1b. 
When treatment duration was varied to 40 years, the ICER 
for IFNβ-1a decreased to US$250,000 (€214,239)/QALY for 
women and US$235,000 (€201,385)/QALY for men.
This study demonstrated the significance of treatment 
duration on the relative cost-effectiveness of the therapies. 
“No treatment” for treatment duration of 6 years was found 
to be the most clinically and cost-effective option as treat-
ments associated with side effects “outweighed the benefits 
of treatment”. Glatiramer acetate was found to be the most 
effective treatment between 6 and 9 years duration, whilst 
treatment of IFNβ-1a was found to be most effective for 
10 years or more. The authors concluded that IFNβ-1a was 
the “best strategy in terms of health outcome”. However, 
the study suffered from assumptions made due to lack of 
information on the age at onset, relapse frequency or type 
of symptoms at onset of disease presented major limitations 
which the authors argued could affect the favorability of 
cost-effectiveness ratios.
In an evaluation of the cost-effectiveness of 4 DMDs in 
the treatment of RRMS and SPMS,98 3 IFNβs and glatiramer 
acetate were compared to no treatment in a 20-year model, 
with cost per QALY being the main outcome measure. 
Using data from the literature, the model simulated the 
clinical course of MS by using 10 point EDSS health states 
(RRMS from point 0 to 10; SPMS from point 2 to 10). 
IFNβ-1a 6 MIU/week (Avonex) proved to be the most 
cost-effective at £42,041 (€67,384) per QALY gained. The 
least cost-effective was glatiramer acetate with 20 mg/week 
(Copaxone) at £97,636 [€156,493]) per QALY gained. 
The probability that any of the interventions would be less 
than a WTP threshold of £20,000 (€32,056) was between 
3% and 18%. Due to the uncertainty surrounding the point 
estimates of cost-effectiveness, the authors suggested 
further research to establish the actual benefit derived from 
the treatment – specifically delays in relation to disease 
progression. The authors also recommended “real data” on 
the progress of people once treatment has ceased.
interferon and mitoxantrone
Touchette et al119 aimed to compare the cost-utility of IV 
MH and SC IFNβ-1b with routine supportive care in patients 
with progressive relapsing MS (PRMS) and SPMS. The IV 
MH was administered every 3 months compared to the IFN, 
which was administered every other day. A Markov model 
was populated using EDSS level 3 as an entering point 
(using existing published data including the MIMS study,91 
EUSPMS study63 and utility measures from Parkin).100 
Patients’ disease progression was followed for 10 years 
and the study was undertaken from both the insurer’s and 
societal perspectives, with data gathered from Olmsted 
County (MMSDPC study).120 IV MH resulted in 5.0860 
QALYS costing US$53,378 (€53,007), compared with rou-
tine supportive care (4.9650 QALYS over 10-years costing 
US$46,331 (€46,009)). IFN produced a QALY of 5.17 with 
a cost estimate of US$115,833 (€115,028). From a societal 
perspective, IV MH was US$378,464 (€375,833) with IFN 
remaining the most costly at US$433,932 (€430,916). When 
compared with routine supportive care, the IV MH resulted 
in a cost-utility ratio of US$58,272 (€57,867) per QALY, 
and from the societal perspective, IV MH was less costly 
and produced larger QALY gains.
The cost-utility ratios for IFN were higher from both the 
insurer and societal perspective (US$338,738 (€336,383) and 
US$245,700 (€243,992) respectively, compared to routine 
care. The mean cost-utility ratio for IFNβ-1b relative to MH 
was US$741,044 (95% CIs: –US$6,564,807, US$7,482,341) 
and likely to be less than US$100,000 on less than 1% of 
occasions. The authors concluded that from the insurers’ 
perspective, IV MH in patients with PRMS and SPMS with 
EDSS scores of between 3 and 6 was a cost-effective option. 
From a societal perspective it represented a cost saving. 
Conversely, IFN treatment was not seen to be cost-effective 
in the population with the results being sensitive to both 
the clinical and cost-effectiveness of IV MH. However, the 
analysis suffers from the same limitations as those in Parkin’s 
study100 with regard to the use of utility measures.
Discussion and conclusion
The evaluation of DMDs for the treatment of MS provides 
an excellent scenario for illustrating the complexities 
involved in attempting to integrate the evidence relating 
to effectiveness and resource utilization. A number of 
useful frameworks and matrices have been proposed. For 
example, interventions with cost-QALY ratios of between 
$4,839 (€5,562) and $32,258 (€37,078) were adjudged to 
be cost-effective when there was good clinical evidence ClinicoEconomics and Outcomes Research 2009:1 75
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of their effectiveness,121 while this has been adapted more 
recently as an aide for decision-makers.122 Another issue is 
what actually is a reasonable indicator of cost-effectiveness? 
It has been argued, for example, that NICE is more likely to 
view a technology favorably, subject to other relevant factors, 
if it costs less that $48,387 (€55,617) per QALY,123 while 
the risk sharing scheme for MS treatments has a threshold 
of $58,065 (€66,741) per QALY.124 Other studies have sug-
gested that a cost per QALY threshold of $50,000 (€57,471) 
is appropriate,125,126 while a survey of health economists has 
suggested a threshold of $60,000 (€68,966).110
The papers discussed in this review represent the wealth 
of information available to decision makers in relation to 
DMDs in the treatment of MS. However, all papers have 
limitations associated with them, which mean that the 
conclusions derived from a review of cost-effectiveness 
studies of DMDs remain equivocal. Issues relating to model 
design,15,100,101,107,113 use of natural history data and, reliance 
on clinical data that are subject to a variety of interpretations 
have been common features of studies undertaken to date and 
have conspired to generate an evidence-base that is at best 
muddled and inconclusive .
Recent studies have benefited from more relevant and up-to-
date data relating to disease progression15,83,92,96,98,99,102,111,113,118 
and have generally produced more favorable cost-effective-
ness ratios, which are reflected in the cost-effectiveness 
acceptability curves produced. It therefore may be reason-
able to conclude that the cost-effectiveness of interventions 
improves when longer time perspectives are employed, and 
the models reflect the progression of disease experienced by 
patients.15,96 As well as the time horizon, the estimates are 
highly sensitive to the approach taken to discounting costs 
and benefits; the cost of the therapies; the costs of patient 
management; disease progression, with and without treat-
ment, and what happens to patients when they stop treatment; 
the impact of MS on carers in terms of utility loss and costs 
incurred; the effect of non-responders and adverse events 
associated with the therapies; the relationship between dis-
ability levels and utility losses and the extent to which indirect 
costs are included.
In conclusion, it would appear that the balance of 
evidence suggests that DMDs for patients with MS are not 
cost-effective when measured against prevailing cost/QALY 
thresholds. However, more recent studies have tended to 
tilt this balance and demonstrated a trend in producing 
lower cost-effectiveness ratios, which are either within 
thresholds or are reasonably close to them. Further, the use 
of cost-effectiveness acceptability curves in more recent 
studies has also served to highlight the likelihood that DMDs 
can be viewed as representing value for money. As more 
appropriate, robust information becomes available over the 
lifetime of the disease and as greater numbers of patient his-
tories become documented, it is to be hoped that the quantity 
and quality of evidence on the impact of the drugs on disease 
progression clarifies issues relating to the effectiveness of 
the treatments, which, in turn, can lead to more informed 
judgement to place alongside the evidence-base in relation 
to decision making.
In addition, there are currently several major trials 
looking at the efficacy of new DMDs such as alemtuzumab 
(Phase III), Fingolimod (Phase III), cladribine (Phase III) and 
the controversial cannabinoid Sativex (Phase I). Therefore, 
it seems timely that developments in the field of health eco-
nomics will hopefully address the methodological difficul-
ties associated with modeling disease progression in order 
to move towards a consensus relating to the extent to which 
DMDs in the treatment of patients with MS can be regarded 
as being cost-effective.
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